Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Mabworks Biotech

Request full access

Biopharmaceutical company developing antibody therapies for autoimmune diseases and cancer

Dongcheng District, ChinaFounded 2003Biotech & Life Sciences

About Beijing Mabworks Biotech

Beijing Mabworks Biotech (MabWorks) is a biopharmaceutical company founded in 2003 that discovers, develops, manufactures and commercializes therapeutic antibodies for oncology and autoimmune indications. The company has built proprietary antibody technology platforms covering the full discovery-to-development pipeline: an ADCC-enhanced antibody platform, a multispecific antibody platform, an antibody discovery and optimization platform, a half-life extended antibody platform, and a CMC and manufacturing platform. These enable the design and selection of differentiated antibody drug candidates with improved efficacy, safety and pharmacokinetic properties.

MabWorks' lead product, Bejescin (MIL62), a third-generation recombinant humanized anti-CD20 antibody developed on its ADCC-enhanced platform, was approved by China's NMPA in February 2026 for neuromyelitis optica spectrum disorder (NMOSD) and primary membranous nephropathy (pMN), becoming the world's first drug approved for the pMN indication and the first domestically developed NMOSD treatment in China. The pipeline also includes MBS303/MSC303, a CD20/CD3 T-cell engager, MBS314, a GPRC5D/BCMA/CD3 multispecific antibody, and MIL116, an anti-APRIL antibody for IgA nephropathy, among more than 15 clinical and preclinical programs.

The company operates an R&D-driven model that combines internal development with out-licensing and strategic collaborations with pharmaceutical partners in China and globally, including an exclusive licensing agreement with Climb Bio for an anti-APRIL antibody outside Greater China. MabWorks is traded on the National Equities Exchange and Quotations (NEEQ: 874070) and is headquartered in the Beijing Economic-Technological Development Area.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
25.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Apr 2020 $160M $640M CITIC Securities · LYZZ Capital · Lake Bleu Capital · Sealand Innovation ↗
SERIES BOther financing Jan 2017 $39M $156M ShenZhen GTJA Investment Group —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Mabworks Biotech website traffic

Latest recorded traffic for Beijing Mabworks Biotech is 330 monthly website visits, down 62.9% over the last three months. Beijing Mabworks Biotech's team grew 0% over the past year.

Latest monthly visits330 3-month web change-62.9% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Mabworks Biotech in the Dongcheng District ecosystem

Live from Dealroom

The Beijing Mabworks Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Med-Fine Capital
  • ShenZhen GTJA Investment Group

Series B and later9 investors entered at this stage

  • CICC
  • CITIC Securities
  • LYZZ Capital
  • Lake Bleu Capital
  • Sealand Innovation
  • E-Town Capital
  • Yue Xiu Enterprises
  • Huge Capital
  • SDIC Unity Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Mabworks Biotech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Mabworks Biotech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.